

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING

HELD ON WEDNESDAY, JUNE 25, 2025

(2) ELECTION OF THE NEW SESSION OF THE BOARD

**(3) ELECTION OF THE NEW SESSION OF THE SUPERVISORY
COMMITTEE**

(4) APPOINTMENT OF CHAIRMAN OF THE BOARD

**(5) APPOINTMENT OF MEMBERS OF BOARD COMMITTEES
AND**

(6) APPOINTMENT OF CHAIRMAN OF THE SUPERVISORY COMMITTEE

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) is pleased to announce the poll results of the annual general meeting (the “**AGM**”) held on Wednesday, June 25, 2025.

For details of the resolutions considered at the AGM, the shareholders of the Company (the “**Shareholders**”) may refer to the notice of the AGM and the Company’s circular both dated May 30, 2025 (the “**Circular**”). Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Circular.

CONVENING AND ATTENDANCE OF THE AGM

The AGM was held as an on-site meeting at Conference Room 3, 2nd Floor, Building C2-1, No. 666 Gaoxin Road, East Lake High Tech Development Zone, Wuhan, Hubei Province, PRC on Wednesday, June 25, 2025.

The AGM was convened by the Board and hosted by Dr. Zhou Pengfei, the chairman of the Board. All the Directors (except for Dr. Cheng Bin, who was unable to attend due to work-related reasons) attended the AGM, either in person or online.

The convention of the AGM was in compliance with the requirements of the applicable PRC laws and regulations, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company (the “**Articles of Association**”). All the proposed resolutions as set out in the notice of the AGM were tabled before the AGM for Shareholders’ consideration and approval, and were put to vote by way of poll.

To the best knowledge of the Board, having made reasonable inquiries (i) there was no restriction on any Shareholder casting votes on any proposed resolution at the AGM; (ii) no Shareholder has a material interest in the matter considered at the AGM and was required to abstain from voting at the AGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favour of the resolution proposed at the AGM as set out in Rule 13.40 of the Listing Rules; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any resolution proposed at the AGM.

POLL RESULTS OF THE AGM

As at the date of the AGM, the total number of issued Shares and Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM was 193,849,200, including 82,380,386 Unlisted Shares and 111,468,814 H Shares. The number of Shareholders and authorized proxies attended the AGM was three. Shareholders and authorized proxies holding an aggregate of 165,254,959 Shares attended the AGM, representing approximately 85.25% of the total number of Shares with voting rights.

At the AGM, the following resolutions were considered and passed by registered poll and the poll results are set out as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the Annual Report for 2024.	165,254,959 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the report of the Board of Directors for 2024 of the Company.	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
3.	To consider and approve the report of the Supervisory Committee for 2024 of the Company.	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
4.	To consider and approve the financial report for 2024 of the Company.	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
5.	To consider and approve the profit distribution plan for 2024 of the Company.	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
6.	To consider and approve the proposed reappointment of Deloitte Touche Tohmatsu as the auditor of the Company for 2025 and to authorize the Board to determine their remuneration.	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
7.	To consider and approve the election of the new session of the board.			
7.1	Election of Dr. Zhou Pengfei as executive Director, and to authorize the Board to determine his remuneration;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.2	Election of Mr. Wen Zhicheng as executive Director, and to authorize the Board to determine his remuneration;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.3	Election of Dr. Yuan Qian as non-executive Director;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.4	Election of Dr. Zhou Hongfeng as non-executive Director;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.5	Election of Mr. Pang Zhenhai as non-executive Director;	154,761,918 (93.65%)	8,286,000 (5.01%)	2,207,041 (1.34%)
7.6	Election of Dr. Hui Xiwu as non-executive Director;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.7	Election of Mr. Xie Shouwu as non-executive Director;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.8	Election of Dr. Cheng Bin as independent non-executive Director, and to authorize the Board to determine his remuneration;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.9	Election of Ms. Fu Lili as independent non-executive Director, and to authorize the Board to determine her remuneration;	155,721,501 (94.23%)	8,286,000 (5.01%)	1,247,458 (0.75%)
7.10	Election of Dr. Deng Yuezhen as independent non-executive Director, and to authorize the Board to determine his remuneration;	152,020,629 (91.99%)	8,286,000 (5.01%)	4,948,330 (2.99%)
7.11	Election of Dr. Chen Bin as independent non-executive Director, and to authorize the Board to determine his remuneration.	152,020,629 (91.99%)	8,286,000 (5.01%)	4,948,330 (2.99%)

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
8	To consider and approve the election of the new session of the Supervisory Committee.			
8.1	Election of Mr. Wang Junming as Shareholder representative Supervisor;	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
8.2	Election of Ms. Liu Fang as Shareholder representative Supervisor;	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
8.3	Election of Mr. Ji Changtao as Shareholder representative Supervisor.	164,007,501 (99.25%)	0 (0.00%)	1,247,458 (0.75%)
9.	To consider and approve the proposed amendments to the Rules of Procedures for the General Meeting of Shareholders (《股東大會議事規則》).	162,088,335 (98.08%)	1,919,166 (1.16%)	1,247,458 (0.75%)
Special Resolutions		Number of Votes (%)		
		For	Against	Abstain
10.	To consider and approve the proposed grant of Issuance Mandate.	160,027,470 (96.84%)	1,620,448 (0.98%)	3,607,041 (2.18%)
11.	To consider and approve the proposed amendments to the Articles of Association.	145,402,335 (87.99%)	18,605,166 (11.26%)	1,247,458 (0.75%)

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 9, such resolutions were duly passed as ordinary resolutions. As more than two-thirds of the votes were cast in favour of each of the resolutions numbered 10 and 11, such resolutions were duly passed as special resolutions.

SCRUTINEERS

The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two Shareholders' representatives, two Supervisors of the Company and a lawyer from DACHENG LAW OFFICES LLP (WUHAN), the PRC legal adviser of the Company, served as the scrutineers of the AGM for scrutinizing and counting votes.

ELECTION OF THE NEW SESSION OF THE BOARD

Upon approval by the Shareholders at the AGM, Dr. Zhou Pengfei and Mr. Wen Zhicheng were appointed as executive Directors of the second session of the Board; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu were appointed as non-executive Directors of the second session of the Board; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezheng and Dr. Chen Bin were appointed as independent non-executive Directors of the second session of the Board. The term of office of the aforesaid Directors shall be three years with effective from June 25, 2025 until the expiration of the term of office of the second session of the Board.

The Company has renewed the service contract with each Director. Independent non-executive Directors are entitled to an allowance of RMB268,000 per annum (before tax). Other than independent non-executive Directors, the Company does not pay Directors' fee to other Directors, except for the corresponding remuneration to be paid in accordance with their positions in the Company with reference to the relevant rules of the Company. The details of their remuneration will be disclosed in the annual report of the Company.

The biographical details of the aforesaid Directors have been set out in the Circular in accordance with Rule 13.51(2) of the Listing Rules. As at the date of this announcement, there is no change to such information. The aforesaid independent non-executive Directors have confirmed that they have met the independence criteria set out in Rule 3.13 of the Listing Rules. The Company has assessed their independence and believed that they met the independence criteria set out in Rule 3.13 of the Listing Rules and were independent individuals.

Due to the expiration of the term of office, Ms. Liang Qian retired as a non-executive Director of the Company with effective from June 25, 2025. As at the date of this announcement, the Board has not received from Ms. Liang Qian any disagreement between her and the Board relating to her retirement and there are no other matters relating to her retirement that need to be brought to the attention of the Stock Exchange and the Shareholders. The Company would like to take this opportunity to thank Ms. Liang Qian for her valuable contribution to the Company.

ELECTION OF THE NEW SESSION OF THE SUPERVISORY COMMITTEE

Upon approval by the Shareholders at the AGM, Mr. Wang Junming, Ms. Liu Fang and Mr. Ji Changtao were appointed as the Shareholder representative Supervisors of the second session of the Supervisory Committee. Mr. Zhang Jing and Ms. Xiao Ying were elected as employee representative Supervisors by the employees of the Company at the employees' representative congress or other forms of democratic election, to join the second session of the Supervisory Committee directly. The term of office of the aforesaid Supervisors shall be three years with effective from June 25, 2025 until the expiration of the term of office of the second session of the Supervisory Committee.

The Company has entered into or renewed the service contract with each Supervisor. The Supervisors will not receive any Supervisor's fee from the Company, but will receive the corresponding remuneration in accordance with their positions in the Company. The details of their remuneration will be disclosed in the annual report of the Company.

The biographical details of the aforesaid Shareholder representative Supervisors have been set out in the Circular in accordance with Rule 13.51(2) of the Listing Rules. The biographical details of the employee representative Supervisor have been set out in the Annual Report for 2024. As at the date of this announcement, there is no change to such information.

Due to the expiration of the term of office, Mr. Sun Jumin retired as a Supervisor of the Company with effective from June 25, 2025. As at the date of this announcement, neither the Board nor the Supervisory Committee has received from Mr. Sun Jumin any disagreement between him and the Board or the Supervisory Committee relating to his retirement, and there are no matters relating to his retirement that need to be brought to the attention of the Stock Exchange and the Shareholders. The Company would like to take this opportunity to thank Mr. Sun Jumin for his valuable contribution to the Company.

APPOINTMENT OF CHAIRMAN OF THE BOARD

The Board is pleased to announce that, in accordance with the relevant provisions of the Articles of Association, the Board agreed to elect Dr. Zhou Pengfei as the chairman of the Board of the Company for a term consistent with that of the second session of the Board.

APPOINTMENT OF MEMBERS OF BOARD COMMITTEES

The Board has decided to appoint the members of committees of the second session of the Board. The members of each committee are as follows:

(I) Audit Committee

Chairman: Ms. Fu Lili

Members: Dr. Zhou Hongfeng, Dr. Deng Yuezhen

(II) Nomination Committee

Chairman: Dr. Zhou Pengfei

Members: Dr. Cheng Bin, Ms. Fu Lili

(III) Remuneration Committee

Chairman: Dr. Cheng Bin

Members: Dr. Yuan Qian, Dr. Chen Bin

The term of office of the members of committees is consistent with the term of office of the second session of the Board.

APPOINTMENT OF CHAIRMAN OF THE SUPERVISORY COMMITTEE

The Supervisory Committee announces that, in accordance with the relevant provisions of the Articles of Association, the Supervisory Committee agreed to elect Mr. Wang Junming as the chairman of the Supervisory Committee of the Company for a term of office consistent with that of the second session of the Supervisory Committee.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Wuhan, PRC, June 25, 2025

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive Directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.